Novocure reported that its electric fields therapy, when combined with chemoradiation, failed to extend survival in a key phase 3 glioblastoma study. The company said the negative result reduces the likelihood of expanding the treatment’s label based on this dataset. The report indicated dampened expectations for broader use while reinforcing the difficulty of improving outcomes in high-grade glioma beyond current standard approaches. The result is likely to affect near-term planning for evidence generation and future trial design. Investors will now focus on what, if any, subsets or alternative endpoints could support regulatory and commercial strategy, and whether additional trials are needed to restore confidence in the platform’s clinical profile.